David C. Myles
CIK: 0001831216
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Olema Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Feb 2, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
250K shares- - Feb 2, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectPerformance Stock Options (Right to Buy)
106.3K shares- - Jan 14, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct15K shares at avg. $28.60$429K - Jan 14, 2026OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $4.87$244K - Jan 14, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct35K shares at avg. $28.99$1.0M - Jan 13, 2026OLMA
Olema Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $4.87$244K - Jan 13, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct49.8K shares at avg. $27.60$1.4M - Jan 13, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct200 shares at avg. $28.49$6K - Jan 12, 2026OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Indirect10K shares at avg. $28.34$283K - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Gift(G)Direct9K shares- - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct1.2K shares at avg. $28.08$34K - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct43.7K shares at avg. $30.40$1.3M - Dec 19, 2025OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct6K shares at avg. $31.39$190K - Feb 28, 2025OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (Right to Buy)
205K shares- - Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct13.3K shares at avg. $8.66$115K - Dec 11, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct300 shares at avg. $9.39$3K - Dec 10, 2024OLMA
Olema Pharmaceuticals, Inc.
Sale(S)Direct12.5K shares at avg. $9.38$117K - Dec 9, 2024OLMA
Olema Pharmaceuticals, Inc.
Award(A)Direct48.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 2, 2026 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 250,000 | - | - | Direct |
| Feb 2, 2026 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Performance Stock Options (Right to Buy) | 106,250 | - | - | Direct |
| Jan 14, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 14,997 | $28.60 | $428,914 | Direct |
| Jan 14, 2026 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $4.87 | $243,500 | Direct |
| Jan 14, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 35,003 | $28.99 | $1,014,737 | Direct |
| Jan 13, 2026 | OLMA Olema Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $4.87 | $243,500 | Direct |
| Jan 13, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 49,800 | $27.60 | $1,374,480 | Direct |
| Jan 13, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 200 | $28.49 | $5,698 | Direct |
| Jan 12, 2026 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 10,000 | $28.34 | $283,400 | Indirect |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Gift(G) | 9,000 | - | - | Direct |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 1,225 | $28.08 | $34,398 | Direct |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 43,729 | $30.40 | $1,329,362 | Direct |
| Dec 19, 2025 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 6,046 | $31.39 | $189,784 | Direct |
| Feb 28, 2025 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (Right to Buy) | 205,000 | - | - | Direct |
| Dec 11, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 13,314 | $8.66 | $115,299 | Direct |
| Dec 11, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 300 | $9.39 | $2,817 | Direct |
| Dec 10, 2024 | OLMA Olema Pharmaceuticals, Inc. | Sale(S) | 12,452 | $9.38 | $116,800 | Direct |
| Dec 9, 2024 | OLMA Olema Pharmaceuticals, Inc. | Award(A) | 48,750 | - | $0 | Direct |
1-18 of 18 transactions
About Myles David C.
Myles David C. (SEC CIK 0001831216) files insider reports with the SEC as CH. DISCOV. & NON-CLIN DEV OFF of Olema Pharmaceuticals, Inc. (OLMA).
Signal8 holds 5 ownership filings by Myles David C., all Form 4s, filed between Dec 11, 2024 and Feb 4, 2026. Those filings report 18 transactions, from Dec 9, 2024 to Feb 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Myles David C.'s filings is in SAN FRANCISCO, CA.
Recent filings by Myles David C.
- Feb 2, 2026: Grants or awards of OLMA derivative securities (2 lines, Form 4, code A).
- Jan 14, 2026: Open-market sale of OLMA shares (Form 4, code S).
- Jan 14, 2026: Option exercise of OLMA shares (Form 4, code M).
- Jan 14, 2026: Open-market sale of OLMA shares (Form 4, code S).
- Jan 13, 2026: Option exercise of OLMA shares (Form 4, code M).
Other insiders filing for Olema Pharmaceuticals, Inc. (OLMA)
- O'Byrne Jason, CHIEF FINANCIAL OFFICER
- Harmon Cyrus, Director
- BVF PARTNERS L P/IL, Director
- BUTITTA CYNTHIA M, Director
- Garland J. Scott, Director
- Hrustanovic Gorjan, Director